Philip Arlen

Company: Precision Biologics Inc.

Job title: President & Chief Executive Officer

Seminars:

Delving into the Mechanism of Action of Neoantigen Antibodies to Aid the Development of Highly Effective Combination Strategy Towards More Successful Therapies 4:00 pm

What is the mechanism of action of a neoantigen antibody being used in combination? How to effectively use the neoantigen antibody, should it be applied before the checkpoint inhibitor or after? Would it be beneficial to combine with more than one other approach?Read more

day: Day Two

Panel Discussion: Evaluating Different Combination Strategies to Develop More Effective Cancer Treatments for Curing the Patients in Need 2:30 pm

Which of the current state of the art immunotherapies are likely to combine well with neoantigen therapies? Beyond checkpoint inhibitors, what combinations seem the most promising? Are there certain combinations which work better for different stages of cancer? Discussing combining neoantigen therapies with PD-L1 therapies, chemotherapies and immunoglobins.Read more

day: Day Two